Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Motherwell is a multi-ingredient dietary supplement (nutraceutical) developed by the Centre for Addiction and Mental Health (CAMH) in Toronto to prevent and reduce postpartum blues (PPB) and associated mood symptoms. Invented by Dr. Jeffrey Meyer, the supplement is formulated with a combination of blueberry juice and extract (providing antioxidants), tryptophan (2 g), and tyrosine (10 g). It is specifically designed to be administered over days 3–5 postpartum to counteract the surge of monoamine oxidase A (MAO-A) protein in the brain. This surge typically depletes mood-supporting neurotransmitters such as serotonin, norepinephrine, and dopamine; Motherwell provides the necessary amino acid precursors and antioxidants to maintain these levels. The product has been licensed to the international women's health company Exeltis and is marketed under the brand name Blues Away®.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Motherwell.